That's just it, no timetable has been given. In previous email, only "clarification" was needed after back and forth with FDA. Now, 4 months later the next PR says that further safety tests are needed (it took 4 months to figure that out!???).
No time frame of call and no time frame for testing and latest financials showed no money spent on R&D in qtr. So I have finally had to ask myself, "Is this a real company?" With the work needed for the divvy payout, I thought it was. I now believe Koos thought they were going to get the IND approval for HemaXellerate I with previous submission and he was lining everything up for that. When the IND went sour, he left us in the dark and stalled for time, maybe allowing close associates to slowly sell some stock before the PR.
Now the PR doesn't give us any time frame to judge. He probably has to find a GLP lab, find funding and then go forward. Meanwhile, other companies are getting patents related to dedentric cells and the longer this drags on, the more chance big investors go elsewhere. For dCellVax, BMSN previous PR estimated testing to be 1 month for efficacy and FDA toxicology testing to last 4 months and then 1 month for submission. This was to happen first by June 2014, then postponed to August 2014, now we don't know, but my point is that safety testing for FDA IND was estimated to be 5 months from start to finish.
If this has to be redone for both Hema and dCellVax, then we are looking at first qtr of 2015 most likely.
The fact that PR was terribly vague - who would want that to be the first PR of a company's new trading ticker??? The fact that no dates and no specific good news was relayed tells me it is worse than expected and nothing is around the corner. Otherwise, you would put the best foot forward for a company's first PR, wouldn't you think?
AIMO
News 
Market Data 
Discover 
